



MiRXES in 2020:

A YEAR OF ACTION



Take a look back at the key events that defined MiRXES in 2020.



JAN 2020

New decade, new conversations:


MiRXES rang in the new decade by organizing the inaugural non-coding RNA (ncRNA) symposium. From diagnostics to therapeutics, attendees discussed ncRNA's potential to revolutionize biomedicine.



FEB 2020

Fighting COVID-19 with Fortitude:

Heeding the call for COVID-19 diagnostics, MiRXES started manufacturing the Fortitude kit in early February. Today, we produce one million tests weekly, with Fortitude exported to over 40 countries.





Welcome to the land of the rising sun:

With Japan accounting for some of the world's highest rates of gastric cancer, our new subsidiary in Tokyo will allow MiRXES to provide early detection with our flagship product, GASTROClear.

APR 2020



SEPT 2020

Setting the standard:

MiRXES helped establish the world's first national standard on miRNA-based diagnostics. The standard paves the way for future developments in miRNA research, ensuring consistent quality along the way.



OCT 2020

Detecting cancer in the nick of time:

With our clinical collaborators, MiRXES published two papers in high-impact journals detailing the effectiveness of miRNA panels for the early, non-invasive detection of lung and gastric cancer. The publications pave the way for accelerated commercialization of the tests and further development of our multi-cancer early detection pipeline.



NOV 2020

A panoramic view of disease:

Proving that it is possible to achieve more with less, our PanoramamiR panel can help researchers measure nearly 400 miRNAs linked to over 20 diseases in one go.



Dashing the double threat:

Given their similar symptoms, there is a need for a test that can distinguish between COVID-19 and the flu. Building upon our RT-PCR technology, the Fortitude Syndromic Panel achieves this by using virus-specific probes.

DEC 2020

